Table 2.
Antidepressant response by CYP2C19 metaboliser status.
| Low | Moderate | Well | |
|---|---|---|---|
| Metaboliser status | Sertraline (N = 5680) | ||
| Poor | 32 (26%) | 52 (42%) | 39 (32%) |
| Intermediate | 543 (37%) | 551 (37%) | 385 (26%) |
| Normal | 851 (37%) | 825 (36%) | 644 (28%) |
| Rapid | 543 (36%) | 520 (35%) | 430 (29%) |
| Ultrarapid | 93 (35%) | 107 (40%) | 65 (24%) |
| Citalopram (N = 2503) | |||
| Poor | 18 (35%) | 19 (37%) | 14 (27%) |
| Intermediate | 251 (37%) | 232 (34%) | 190 (28%) |
| Normal | 349 (36%) | 376 (39%) | 240 (25%) |
| Rapid | 258 (37%) | 266 (38%) | 179 (25%) |
| Ultrarapid | 45 (41%) | 41 (37%) | 25 (22%) |
| Escitalopram (N = 4342) | |||
| Poor | 26 (34%) | 18 (24%) | 32 (42%) |
| Intermediate | 339 (30%) | 425 (38%) | 351 (31%) |
| Normal | 564 (32%) | 672 (38%) | 526 (30%) |
| Rapid | 369 (31%) | 444 (37%) | 388 (32%) |
| Ultrarapid | 61 (32%) | 66 (35%) | 61 (32%) |
Percentages are presented conditional on antidepressant and metaboliser status (e.g., 26% of poor metabolisers taking sertraline reported a low efficacy).